Table 1.
Parameters |
Placebo group (n = 8) |
Linagliptin group (n = 8) |
||||
10 wk | 14 wk | 18 wk | 10 wk | 14 wk | 18 wk | |
Body weight, g | 35.1 (25.6-47.7) | 33.2 (24.6-50.9) | 37.3 (27.3-51.6) | 37.6 (34.5-44.2) | 39.9 (30.0-42.3) | 41.7 (31.5-45.0) |
Glucose, mg/dL | 637 (549-678) | 579 (551-671) | 610 (506-683) | 651 (631-693) | 588 (520-640) | 625 (601-646) |
Triglycerides, mg/dL | 415 (209-510) | 324 (209-336) | 316 (149-555) | 385 (262-637) | 279 (251-315) | 391 (238-480) |
Total cholesterol, mg/dL | 129 (94-156) | 100 (39-140) | 131 (22-156) | 112 (28-132) | 104 (24-124) | 71 (18-120) |
ALT, U/L | 132 (105-375) | 126 (72-369) | 170 (69-306) | 146 (84-255) | 185 (118-225) | 203 (80-294) |
GGT, U/L | 16.7 (8.2-28.1) | 13 (8.5-25.1) | 14.6 (10.5-16.5) | 14.4 (8.9-18.7) | 12.5 (7.1-22) | 13.6 (10.5-22.7) |
Data are shown as the medians, minimal and maximal values. No significant differences in the variables in both groups at week 10 and 18 (Wilcoxon signed rank test, all P > 0.05). The differences between groups are not significant at week 10, 14 and 18 (U-test, all P > 0.05). ALT: Alanine aminotransferase; GGT: Gamma-glutamyl transpeptidase.